Motif Bio to participate at upcoming Jefferies London Healthcare Conference
31 Octobre 2018 - 8:00AM
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage
biopharmaceutical company specialising in developing novel
antibiotics, announced today that the Company will participate in
the following event:
Jefferies London Healthcare
ConferenceNovember 14-15, 2018London, UK
The Company will host one-on-one meetings at
this conference. Now in its ninth year, the Jefferies
conference is the largest healthcare-dedicated conference in
Europe. In 2017, over 400 companies participated, with 1,800
attendees and 4,500 business-to-business and investor meetings.
For further information please contact:
Motif Bio plc |
info@motifbio.com |
Graham Lumsden (Chief Executive Officer) |
|
|
|
Walbrook PR Ltd. (UK FINANCIAL PR & IR) |
+44 (0) 20 7933 8780 |
Paul McManus/Helen Cresswell/Lianne Cawthorne |
|
|
|
MC Services AG (EUROPEAN IR) |
+49 (0)89 210 2280 |
Raimund Gabriel |
raimund.gabriel@mc-services.eu |
|
|
Solebury Trout (U.S. IR) |
+ 1 (646) 378-2963 |
Meggie Purcell |
mpurcell@troutgroup.com |
|
|
Russo Partners (U.S. PR) |
+1 (858) 717-2310 or +1 (212) 845 4272 |
David Schull |
david.schull@russopartnersllc.com |
Travis Kruse, Ph.D. |
travis.kruse@russopartnersllc.com |
Note to Editors:
About Motif Bio
Motif Bio plc (AIM/NASDAQ: MTFB) is a
clinical-stage biopharmaceutical company focused on developing
novel antibiotics designed to be effective against serious and
life-threatening infections caused by multi-drug resistant
Gram-positive bacteria, including MRSA. The Company’s lead product
candidate is iclaprim. Following positive results from two Phase 3
trials (REVIVE-1 and REVIVE-2), a New Drug Application (NDA) was
submitted to the U.S. Food & Drug Administration (FDA) for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and is now under review, with a PDUFA date of February 13,
2019. More than 3.6 million patients with ABSSSI are hospitalised
annually in the U.S. It is estimated that up to 26% of hospitalized
ABSSSI patients have renal impairment.
The Company also plans to develop iclaprim for
hospital acquired bacterial pneumonia (HABP), including ventilator
associated bacterial pneumonia (VABP), as there is a high unmet
need for new therapies in this indication. A Phase 2 trial in
patients with HABP has been successfully completed and a Phase 3
trial is being planned. Additionally, iclaprim has been granted
orphan drug designation by the FDA for the treatment of
Staphylococcus aureus lung infections in patients with cystic
fibrosis and is in preclinical development for this indication.
Iclaprim has received Qualified Infectious
Disease Product (QIDP) designation from the FDA together with Fast
Track status for the ABSSSI indication. If approved for the ABSSSI
indication as a New Chemical Entity, iclaprim will be eligible for
10 years of market exclusivity in the U.S. from the date of first
approval, under the Generating Antibiotic Incentives Now Act (the
GAIN Act). In Europe, 10 years of market exclusivity is
anticipated. Motif is also building a patent estate to
provide additional protection for iclaprim and has recently
received . Notices of Allowance from the United States Patent
and Trademark Office for two method of use patents that will
expire in 2037.
Forward-Looking Statements
This press release contains forward-looking
statements. Words such as “expect,” “believe,” “intend,” “plan,”
“continue,” “may,” “will,” “anticipate,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Motif
Bio’s actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Motif Bio
believes that these factors include, but are not limited to, (i)
the timing, progress and the results of clinical trials for Motif
Bio’s product candidates, (ii) the timing, scope or likelihood of
regulatory filings and approvals for Motif Bio’s product
candidates, (iii) Motif Bio’s ability to successfully commercialise
its product candidates, (iv) Motif Bio’s ability to effectively
market any product candidates that receive regulatory approval, (v)
Motif Bio’s commercialisation, marketing and manufacturing
capabilities and strategy, (vi) Motif Bio’s expectation regarding
the safety and efficacy of its product candidates, (vii) the
potential clinical utility and benefits of Motif Bio’s product
candidates, (viii) Motif Bio’s ability to advance its product
candidates through various stages of development, especially
through pivotal safety and efficacy trials, (ix) Motif Bio’s
estimates regarding the potential market opportunity for its
product candidates, and (x) the factors discussed in the section
entitled “Risk Factors” in Motif Bio’s Annual Report on Form 20-F
filed with the SEC on April 10, 2018, which is available on the
SEC’s web site, www.sec.gov. Motif Bio undertakes no obligation to
update or revise any forward-looking statements.
Motif Bio (NASDAQ:MTFB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Motif Bio (NASDAQ:MTFB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024